Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-05-02 Sale | 2023-05-03 6:25 pm | Edgewise Therapeutics Inc. | EWTX | Donovan Joanne M. CMO | 3,254 | $8.9049 | $28,977 | 30,794 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2023-08-17 Option Award | 2023-08-18 7:13 pm | N/A 2033-08-17 | Edgewise Therapeutics Inc. | EWTX | Donovan Joanne M. CMO | 200,000 | $0 | 200,000 (Direct) | View |
| 2023-05-01 Exercise | 2023-05-03 6:25 pm | N/A 2032-05-01 | Edgewise Therapeutics Inc. | EWTX | Donovan Joanne M. CMO | 10,416 | $0 | 30,794 (Direct) | View |
| 2022-08-08 Option Award | 2022-08-10 5:41 pm | N/A 2032-08-08 | Edgewise Therapeutics Inc. | EWTX | Donovan Joanne M. CMO | 240,000 | $0 | 240,000 (Direct) | View |
| 2022-05-01 Option Award | 2022-05-03 4:14 pm | N/A 2025-05-01 | Edgewise Therapeutics Inc. | EWTX | Donovan Joanne M. CMO | 31,250 | $0 | 31,250 (Direct) | View |
| 2021-08-17 Option Award | 2021-08-19 5:09 pm | N/A 2031-08-17 | Edgewise Therapeutics Inc. | EWTX | Donovan Joanne M. CMO | 160,000 | $0 | 160,000 (Direct) | View |
| 2021-04-30 Option Award | 2021-05-04 4:34 pm | N/A 2031-04-30 | Edgewise Therapeutics Inc. | EWTX | Donovan Joanne M. CMO | 160,000 | $0 | 160,000 (Direct) | View |
| 2020-02-12 Option Award | 2020-02-14 3:00 pm | N/A 2030-02-11 | CATABASIS PHARMACEUTICALS INC | CATB | Donovan Joanne M. CMO; SVP Clinical Development | 60,000 | $0 | 60,000 (Direct) | View |